Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...

Despite such guidelines, though, the investigators said there is a lack of evidence-based or widely accepted consensus on ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today ...

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...

What at least one investigator has been saying for nearly 2 decades is supported by a new study: 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) can provide important prognostic ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key ...

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

Canine soft tissue sarcomas (STS) constitute a heterogeneous group of mesenchymal tumours that present diverse morphological and clinical profiles. These neoplasms commonly affect the skin and ...